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ABSTRACT: A rapid, economic and sensitive chemiluminescent method involving flow-injection analysis was developed for 
the determination of dipyrone in pharmaceutical preparations. The method is based on the chemiluminescent reaction 
between quinolinic hydrazide and hydrogen peroxide in a strongly alkaline médium, in which vanadium(IV) acts as a 
catalyst. Principal chemical and physical variables involved in the flow-injection system were optimized using a modified 
simplex method. The variations in the quantum yield observed when dipyrone was present in the reaction médium were 
used to determine the concentration of this compound. The proposed method requires no preconcentration steps and 
reliably quantifies dipyrone over the linear range 1-50ug/mL. In addition, a sample throughput of 85 samples/h is possible. 
Copyright © 2011 John Wiley & Sons, Ltd. 
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Introduction 
Dipyrone, also known as metamizol, methanesulphonic acid or 
analgin, is a drug of the pyrazolone (phenylpyrazolone) family 
with analgesic, antipyretic and anti-inflammatory effects. The 
pyrazolones have been widely used in medicine, and dipyrone, 
which was first synthesized in 1920, is now the group's main 
representative (1). Sodium dipyrone (2,3-dihydro-1,5-dimethyl-
3-oxo-2-phenyl-1/-/-pyrazol-4-yl-methylamino-methanesulphonate) 
is one of its most used salts, since it is soluble in water and is an 
effective non-opioid analgesic for treating acute pain. The data 
available on the clinical efficacy of single dose dipyrone in 
postoperative pain management have been analysed by the 
Cochrane Collaboration (2). Compared to a placebo, dipyrone 
showed an NNT valué (i.e. the number needed to treat for pain 
relief of at least 50% for 4-6 h in patients with modérate to 
severe pain) of 2.5 for 500 mg and 1.9 for 1 g. Intramuscularly-
injected dipyrone (2g) has been reported to show a greater 
analgesic effect than lOOmg pethidine, 30 mg ketorolac or 
10 mg morphine. In addition, oral doses of 500 mg and 1g 
dipyrone are reported to be more effective than 400 mg 
ibuprofen, 600 mg aspirin or 1 g paracetamol (3). 
Like many substances, dipyrone has been associated with 
side-effects, in this case agranulocytosis and anaphylactic shock 
reactions (4-6). Its use remains popular in some parts of Europe, 
the Middle East, Asia, África and Latin America, but in others it is 
not registered, and in the UK, Sweden and the USA its use is 
forbidden (2,3). Some research on dipyrone has shown, 
however, that the risks of agranulocytosis are minimal (7), and 
shock reactions are common to all antipyretic analgesics. 
Further, the available evidence suggests that its use is 
associated with no gastric or renal side-effects - common 
problems of analgesics and non-steroidal anti-inflammatory 
drugs (NSAIDs) (8). Indeed, the risk of agranulocytosis should be 
understood in the context of the risks associated with the use of 
other analgesics. Andrade ef al. (9) report the estimated excess 
mortality due to severe side-effects of aspirin to be 185/100 
million and 592/100 million for diclofenac, but only 20/100 
million for paracetamol and 25/100 million for dipyrone. 
Most of the methods used for the determination of this drug 
are based on titrimetry (10,11), amperometry (12-15), spectro-
photometry (16-21), polarography (22), HPLC (23-26) and 
chemiluminescence (27-30). The spectrophotometric and 
chemiluminescent methods, especially when combined with 
flow-injection analysis (FIA), provide economic, simple, sensitive 
and rapid assessment procedures, e.g. the methods of Gregorio 
Alapont ef al. (30), Huang ef al. (29) and Song and Zhang (28) are 
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routinely used in pharmaceutical analysis. However, the 
concentration range that the method of (30) is capable of 
measuring is reduced (2.5-12.5 ng/mL), that of (29) requires 
preconcentration procedures be performed, and the throughput 
of (28) (60/h) could be improved. 
In previous work (31) our group reported that, under certain 
conditions, cyclic hydrazides such as cinchomeronic hydrazide 
(31,33) and quinolinic hydrazide (34,35) undergo chemilumi-
nescent reactions that can be used for the determination of 
compounds such as vanadium and H202. The present work 
describes a method for dipyrone determination involving the 
quinolinic hydrazide-H202-vanadium(IV) system. The proposed 
method is based on the reduction, caused by dipyrone, in the 
quantum yield of the vanadium(IV)-catalysed quinolinic hydra-
zide chemiluminescent reaction Wmax = 420nm). The most 
important reaction conditions and FIA variables of the reaction 
were optimized using a super-modified simplex method (32). 
The simplicity and selectivity of the proposed method allows the 
determination of dipyrone concentrations in pharmaceutical 
preparations without the need for prior separation or pre-
concentration processes. It also uses relatively inexpensive 
equipment and has a high sample throughput (85 samples/h). 
Experimental 
Chemicals and reagents 
Quinolinic hydrazide (QH; 5,8-dione-6,7-dihydro-pyrido(2,3Ó)pyridazine) 
is a cyclical hydrazide with a structure similar to luminol; that used in 
the present work was synthesized in our laboratory following the 
procedure described by Toro et al. (36). Briefly, quinolinic acid, 
hydrazine and water were mixed and heated under reflux for 2h. The 
solid obtained was purified by heating until reaching 250 °C. It was 
then cooled and the product crystallized in water. The crystals were 
h
 Na 03S' 
+ H20 
Figure 1. Chemical structure of dipyrone. 
characterized by infra-red spectrometry, which confirmed them to be 
the desired hydrazide (74% purity). 
A quinolinic hydrazide stock solution of 2.0 x 10"2 mol/L was prepared 
by dissolving 0.82 g of these crystals in 10mL 1 mol/L NaOH (Merck, 
Spain) and then diluting to 250 ml_ with deionized water. A vanadium(IV) 
stock solution of 1.0x10"2 mol/L was prepared from 2.53 g vanadyl 
sulphate (Merck, Spain) by dilution with 10 mL 0.1 mol/L H2S04 (Panreac, 
Spain) and diluting to lOOmL with deionized water and adjusting to pH 
1.9. Hydrogen peroxide solutions of 0.25 mol/L were prepared daily by 
dilution of 2.84mL 30% H202 (Foret, Spain; final volume lOOmL) with 
deionized water. 
A 300mg/L dipyrone stock solution (Fig. 1) was prepared by 
dissolving 150mg of C13H16N3Na04SH20 (Sigma-Aldrich, Germany) in 
500 mL deionized water and adjusting to pH 1.9 with 0.1 mol/L H2S04. 
This stock solution was maintained under refrigeration at 5°C. Working 
standards within the 0.005 and 200 mg/L dipyrone range were prepared 
daily by water dilution of the above stock. 
The pharmaceutical formulations of dipyrone analysed were those 
commercially available in Spain: Nolotil capsules (575 mg), injectable 
Nolotil (2g/5mL) and injectable Metamizol Normon (2g/5mL). For the 
analysis of the capsules, the material from 10 capsules was removed, 
weighed and finely powdered. A sample equivalent to the contents of 
two capsules was homogenized and dissolved in 60 mL water and 
filtered (0.45 um). The residue was washed three times with 10 mL water. 
The pH of the resulting solution was adjusted to 1.9 with 0.1 mol/L 
H2S04 before diluting to lOOmL with deionized water. For the analysis 
of the injectable Nolotil and Metamizol Normon formulations, five 
samples from single boxes were separately mixed. An aliquot of the 
mixture equivalent to the contents of one vial (2mL) was diluted to 
lOOmL with deionized water and adjusted to pH 1.9 with 0.1 mol/L 
H2S04. All the reagents used, with the exception of the quinolinic 
hydrazide, were of analytical grade. Deionized water was prepared using 
a Milli-Q system (Millipore). 
Apparatus 
A Perkin-Elmer LS-50 B spectrofluorimeter equipped with a Labsphere 
(FSA-PE-50L) luminescence accessory (an integrating sphere that 
detects emissions from chemiluminescent reactions) was used to 
measure the light signáis produced in reactions. 
Figure 2 shows the flow-injection manifold used for the detection of 
chemiluminescence. This included a Gilson peristaltic pump (Minipuls 2), 
an Omnifit six-way injection valve, a three-way Omnifit connector and 
an in-house spiral reaction coil made of polytetrafluoroethylene (PTFE) 
tubing (1 m long, i.d. 0.8 mm). This was connected to the integrating 
sphere. The pH of all solutions was recorded using a Metrohm 654 pH 
meter. 
The results obtained with the proposed method were compared to 
those obtained by reverse-phase liquid chromatography (HPLC) (24,25) 
Sample 
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Figure 2. Flow-injection manifold. I, injection valve; RC, reaction coil; C, carrier solution; P, vanadium-dipyrone 
solution; H, hydrazide solution; PTM, photomultiplier; T, connector. 
Table 1. System opt 
Study range 
Starting condition 
Step size 
Optimum conditions 
mization by the simplex 
Quinolinic hydrazide pH 
10-14-(H_ 16) 
11.5 
1.3 
13.2 (HJa 
aEquivalent NaOH concentration = 0.17 mol/L. 
H_, alkaline function. 
method 
Vanadium conc. (mol/L) Vanadium pH H202 conc. (mol/L) 
5 X 1CT5-1CT1 1.5-3.5 7.5 X 10^-4.5 X 1CT2 
1CT3 1.7 5 x 1CT3 
2.4 X 1CT2 0.5 1.1 X 10~2 
3.3 X 10~2 1.9 1.7 X 10~2 
Flow rate (mL/min) 
3.2-6.5 
3.5 
0.8 
4.5 
(reference method), involving an Agilent Technologies 1200 Liquid 
Chromatograph equipped with a diode array detector (DAD), a 
thermostatic column module, a quaternary pump and an Agilent Eclipse 
XDB-C1S LC column (5 um particle size, 4.6mmx150mm i.d.). The 
¡njection volume was 100 uL and the DAD wavelength 254.4 nm. 
Quantum yield of the system and dipyrone estimation 
To study the quantum yield of the HQ-H202-vanadium(IV) [V(IV)] system 
¡n the absence of dipyrone, sample solutions of V(IV) (in the range 
2x10~3-1 ug/mL) were prepared by serial dilution of the stock solution. 
All solutions were adjusted to the optimum working pH of 1.9. Samples 
(1.5mL) were introduced into the chemiluminescence cell though an 
¡njection valve and in an aqueous carrier solution (distilled water at pH 
1.9; flow rate, 4.5 mL/min). 
A solution of quinolinic hydrazide was prepared at 2x10~3 mol/L by 
dilution of the stock solution. Hydrogen peroxide (1.7x 10~3 mol/L) was 
pH-adjusted to 13.2 with 0.17 mol/L NaOH. The quinolinic hydrazide-
H202 solution was pumped at a flow rate of 4.5 mL/min and mixed at the 
junction of the T-piece, with the carrier solution also flowing at a rate of 
4.5 mL/min. The mixture was allowed to immediately enter the reaction 
coil. Chemiluminescent emissions were then recorded by the detection 
system. All solutions were tested in triplícate. 
For the determination of dipyrone, sample solutions were prepared 
by adding the compound to the V(IV) solution. The dipyrone 
concentration varied in the range 5x10~3-1 ug/mL; the final V(IV) 
concentration in all dipyrone solutions was 3.29x10~3 mol/L. Light 
emissions were then recorded again. 
The HPLC comparison determinations were undertaken using 
methanol and water (65:35, v/v) as mobile phases A and B. The flow 
rate was 0.6 mL/min. Under these conditions, the retention time of 
dipyrone was 3.25 min. 
System optimization 
In this study the systematic super-modrfied simplex multivariate method 
was used, which varies all the parameters to find the shortest path to the 
optimum. It is generally recommended in the simplex that the number 
of variables does not exceed five or six, so as not to créate a very 
complex system. Initially, experiments were conducted to control the 
temperature, the presence of oxygen and buffer addition. Because these 
variables had no signrñcant influence, they were removed from the 
Simplex system. There was a univariate optimization of ¡njection volume, 
photomultiplier voltage and concentration of hydrazide and a simplex 
multivariate optimization of the five main variables: the concentration 
and pH of the vanadium solution, the pH of the quinolinic hydrazide 
solution, the H202 concentration and the carrier flow rate, making a total 
of 135 experiments in this part. 
Five main system variables were optimized using the super-modrñed 
simplex method (32) (Table 1) before preparing the calibration curve or 
performing dipyrone estimations. Multivariate sequential optimization 
methods, such as the simplex method, allow the simultaneous 
variation of the different variables affecting the response of the 
Table 2. Variation of che 
pH range 
10-11.5 
11.5-12.5 
12.5-13.2 (HJ 
Optimum 13.2 (HJ 
> 13.2 (HJ 
H_, alkaline function. 
miluminescence intensity with pH 
Chemiluminescence 
(%) 
6 
43 
82 
100 
90 
system, providing the shortest route to the optimal conditions. This is 
more efficient and accurate than univariate optimization methods. The 
latter are more simple to perform and are probably the most widely 
used in chemistry, but univariate methods suffer from strong 
interactions between variables, increasing the probability of a false 
optimum being returned (indeed, this is quite common). The loop 
volume of the ¡njection valve (1.5mL) and the voltage of the 
photomultiplier (830 V) were previously optimized and therefore were 
not included among these variables. The ¡njection volume that 
provided the highest quantum yield of the system was determined 
by injecting different times at a constant flow rate. The ranges of the 
above five variables were optimized by taking into account the data 
obtained in previous quinolinic hydrazide chemiluminescence studies 
(34,35), in which FIA techniques were not used. The fixed variables 
were: quinolinic hydrazide concentration, 2.0 x10~3 mol/L; vanadium 
¡njection volume, 1.5 mL; and photomultiplier voltage, 830V. 
For quinolinic hydrazide solution pH values>13.0, the alkaline 
function (HJ was used (37) (expressed as NaOH concentration). 
Table 2 shows the variation in chemiluminescence intensity with pH. 
These results confirm that the reaction is dependent on pH and that a 
strongly alkaline médium is required for the best results. 
Results and discussion 
Figure 3 shows the vanadium(IV)-catalysed mechanism of 
reaction between quinolinic hydrazide and H202. Dipyrone 
reduces the quantum yield by interfering with reaction (A), i.e. 
the formation of the semidione radical. This radical is an 
intermedíate compound in the formation of excited phthalate 
ions, those responsible for light emissions. 
Analytical performance and validation 
The calibration curve for dipyrone determination showed a 
linear interval between 1 and 50ug/mL The experimental data 
fitted a straight line, obtained by the least squares method, with 
a correlation coefficient of /? = 0.998 for n = 7. The equation of 
this line was: / = 879.24 (± 6.67) - 5.73 (± 0.29) C, where / is the 
relative intensity of the emission and C is the dipyrone 
concentration in ug/mL The detection limit, calculated by the 
method of Miller (38), was 2.52ug/ml_ for a signahnoise (S:N) 
ratio of 3. The quantitation limit (S:N = 10) was 8.4ug/ml_. The 
relative standard deviation (RSD) for seven dipyrone injections 
(15 ug/mL) was 3%. Eighty-five samples can be processed in 1 h. 
Application of the method 
For the injectable formulations, the results and recoveries were 
in good agreement with those provided by the HPLC reference 
procedure. No significant differences in dipyrone concentration 
were seen between the proposed method and HPLC at the 95% 
confidence level (4xP<^tab)/ comparing variances by the 
procedure described by Miller (38) (Table 3). However, for the 
solid formulations the results were not very good, probably due 
to the excipients present. In the Nolotil capsules, magnesium 
stearate is a major excipient. índigo carmine, erythrosine, 
titanium dioxide and gelatin are also present in lesser amounts 
(Table 4). 
Compared to the current chemiluminescent/FIA procedures 
for dipyrone estimation (28-30), the proposed method offers 
certain advantages: (a) the range of dipyrone concentrations 
that can be detected is greater than that offered by the (30) 
method; (b) there is no need for preconcentration, as in the (29) 
method; and (c) the throughput is greater than that of the (28) 
method (85 samples/h compared to 60/h). Table 5 compares the 
characteristics of the proposed method with those of the above 
and several other methods for determining dipyrone 
(15,20,24,25,28-30). 
Conclusión 
This new method for determining dipyrone concentrations in 
injectable pharmaceutical preparations provides results compa-
rable to those obtained using an HPLC reference technique -
but more quickly and cheaply. It also provides advantages over 
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Figure 3. Reaction mechanism between quinolone hydrazide and H202, catalysed by V(IV). 
Table 3. Validation of method for dipyrone determination 
Hydrazide method 
Dipyrone added (ug/mL) Dipyrone found (ug/mL) 
5 5.21 
10 10.21 
15 14.93 
Fexp: F experimental; Ftab: F tabulated. 
S 
-0.48 
-0.5 
-0.44 
n 
8 
7 
7 
HPLC method 
Dipyrone found (ug/mL) 
4.93 
9.50 
14.63 
S 
0.27 
0.26 
0.29 
n 
4 
4 
4 
' e x p 
3.16 
3.69 
2.30 
Ftab (95%) 
14.62 
14.73 
14.73 
Table 4. Dipyrone determination in pharmaceutical formulations 
Sample 
Nolotil (injection) 
Normon (injection) 
Nolotil (capsule) 
Content on label 
400 (mg/mL) 
400 (mg/mL) 
575 (mg) 
aAverage ± SD of 4 determinations. 
bAverage ± SD of 3 determinations. 
Dipyrone concentration ± SD 
QH - H202-V(IV) a 
395.2 ±0.5 (mg/mL) 
400.5 ±0.5 (mg/mL) 
1123.7 ±1.8 (mg) 
HPLCb 
392 ±0.3 (mg/mL) 
397 ±0.3 (mg/mL) 
570 ±1.3 (mg) 
RSD % 
QH-H202-V(IV) 
3.56 
3.51 
1.79 
HPLC 
6 
2.14 
2.6 
Table 5. Comparison wii 
Reaction system 
PDAB 
Luminol-dichromate 
Rodamine 6G-Tween 80 
Lum¡nol-H202-Fe(CN)63~ 
Pt electrode 
Reverse phase-C18-DAD 
Reverse phase-C18-DAD 
QH-H202-V(IV) 
CL, chemiluminescent. 
h other methods 
Detection 
Spectrophotometric 
CL 
CL 
CL 
Amperometric 
HPLC 
HPLC 
CL/FIA 
FIA 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
Linear range (LOD, |jg/mL) 
10-400 (1) 
0.0005-0.05 (2 x 10~5) 
0.05-10 (0.003) 
2.5-12.5 (2.1) 
10-50 (0.009) 
4.5-38 (1.5) 
0.5-100 (0.0004) 
1-50 (2.5) 
Throughput (sarr 
50 
60 
-
87 
48 
-
-
85 
íples/h) Ref. no. 
20 
28 
29 
30 
15 
24 
25 
This study 
the cur rent ly used chemi luminescent /F IA methods . These 
advantages may render the proposed system very suitable for 
the rout ine analysis of d ipyrone in injectable pharmaceutical 
formulat ions. 
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